Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R38 | P59533 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12562484 | 1.00 | TAS2R38 (0.30) | TAS2R38 | |
| SCHEMBL19968214 | 1.00 | TAS2R38 (0.30) | TAS2R38 | |
| SCHEMBL22594505 | 0.73 | — | — | |
| SCHEMBL21442026 | 0.73 | — | — | |
| SCHEMBL12562483 | 0.73 | — | — | |
| SCHEMBL20419649 | 0.73 | — | — | |
| SCHEMBL18804456 | 0.71 | — | — | |
| SCHEMBL18804437 | 0.69 | — | — | |
| SCHEMBL12562482 | 0.69 | ABCB11 (0.31) | — | |
| SCHEMBL12562481 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11545637-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2023-01-03 | — | — | US | disclosed |
| US-20180212163-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2018-07-26 | — | — | US | disclosed |
| US-20170247321-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | ROCHE PALO ALTO LLC (US) | 2017-08-31 | — | — | US | disclosed |
| US-9670151-B2 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-20150266817-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | ROCHE PALO ALTO LLC (US) | 2015-09-24 | — | — | US | disclosed |
| US-8889906-B2 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2014-11-18 | — | — | US | disclosed |
| US-20120088837-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | ROCHE PALO ALTO LLC | 2012-04-12 | — | — | US | disclosed |
| US-8093424-B2 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-7799797-B2 | Arylsulfonyl naphthalene derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-7531577-B2 | Arylsulfonamidyl tetralin derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2009-05-12 | — | — | US | disclosed |
| US-20080293751-A1 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-11-27 | — | — | US | disclosed |
| US-20080015208-A1 | Arylsulfonamidyl tetralin derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-01-17 | — | — | US | disclosed |
| US-7312359-B2 | 2-(5-Benzenesulfonyl-indan-1-yl)-ethylamine, used as selective serotonin receptor antagonists for treatment of nervous system and gastrointestinal disorders | ROCHE PALO ALTO LLC (US) | 2007-12-25 | — | — | US | disclosed |
| US-20070293526-A1 | Arylsulfonyl naphthalene derivatives and uses thereof | ROCHE PALO ALTO LLC | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180212163-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD2, OCIAD1, ICOSLG | TAS2R38 1853/4885 |
| US-20080015208-A1 | Arylsulfonamidyl tetralin derivatives and uses thereof | HTR6, TPH1, HTR1B | TAS2R38 897/4885 |
| US-20070293526-A1 | Arylsulfonyl naphthalene derivatives and uses thereof | ARSA, AR, SULT2A1 | TAS2R38 2592/4885 |
| US-11545637-B2 | Organic electroluminescent materials and devices | OCIAD2, OCIAD1, ICOSLG | TAS2R38 1853/4885 |
| US-20080293751-A1 | Tetralin and indane derivatives and uses thereof | INSRR, RIF1, TTR | TAS2R38 513/4885 |
| US-20120088837-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | INSRR, RIF1, TTR | TAS2R38 513/4885 |
| US-20150266817-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | INSRR, RIF1, TTR | TAS2R38 513/4885 |
| US-20170247321-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | ERLIN1, INSRR, PSEN1 | TAS2R38 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.